Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for c…
The bill amends the Medicare hospital inpatient payment rules (section 1886(d)(5)(K)) to allow certain FDA-designated ``breakthrough devices'' to receive conditional New Technology Add-On Payments (NTAP) even if they miss the usual regulatory deadline, provided the device receives FDA approval, clearance, or authorization under 510(k), 513(f)(2), or 515 before July 1 of the fiscal year for which the NTAP application was made. It defines ``breakthrough device'' as one designated under the FDA's expedited 515B breakthrough program and approved for the designated indication.
Safety and evidence standards: liberals emphasize concerns about devices cleared via 510(k) and want stronger post-market data; conservatives emphasize faster access and are less worried about expedited pathways.
Relative to its intended legislative type, this bill is a narrowly focused substantive policy change that amends Medicare payment law to expand NTAP eligibility for FDA-designated breakthrough devices.
The bill amends the Medicare hospital inpatient payment rules (section 1886(d)(5)(K)) to allow certain FDA-designated ``breakthrough devices'' to receive conditional New Technology Add-On Payments (NTAP) even if they miss the usual regulatory deadline, provided the device receives FDA approval, clearance, or authorization under 510(k), 513(f)(2), or 515 before July 1 of the fiscal year for which the NTAP application was made.
It defines ``breakthrough device'' as one designated under the FDA's expedited 515B breakthrough program and approved for the designated indication.
The provision must be implemented in a budget-neutral manner and applies to qualifying breakthrough devices approved/cleared/authorized on or after July 1, 2023.
Content-wise this is a narrow, technical amendment that fits established patterns of incremental Medicare fixes which often succeed, particularly when backed by industry and patient groups. The bill's modest scope and built-in limits raise its prospects. Key barriers are procedural (committee consideration, CBO scoring, Senate floor procedures) and potential pushback if the budget-neutrality claim is found unworkable or if CMS implementation raises cost concerns.
Relative to its intended legislative type, this bill is a narrowly focused substantive policy change that amends Medicare payment law to expand NTAP eligibility for FDA-designated breakthrough devices. It provides targeted statutory text, a definition of the covered devices, effective dates, and a budget-neutrality requirement, while relying on existing NTAP processes for implementation.
Safety and evidence standards: liberals emphasize concerns about devices cleared via 510(k) and want stronger post-market data; conservatives emphasize faster access and are less worried about expedited pathways.
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety and evidence standards: liberals emphasize concerns about devices cleared via 510(k) and want stronger post-market data; conservatives emphasize faster access and are less worried about expedited pathways.
A mainstream progressive would likely welcome measures that reduce delays in beneficiary access to promising medical technologies, especially if those technologies demonstrably improve health outcomes.
However, they would be cautious about expanding payment eligibility for devices that might have limited pre-market evidence (for example, devices cleared via 510(k)), and concerned that the requirement for budget neutrality could shift costs onto other Medicare services or beneficiaries.
They would want strong post-market surveillance, transparency about evidence and price, and protections to ensure equity of access.
A pragmatic centrist would view the bill as a targeted, technical fix to reduce timing barriers between FDA clearance/approval and Medicare payment, which could deliver patient benefits without large new entitlements.
They would appreciate the budget-neutral requirement but want clarity on how CMS will implement offsets and monitor outcomes.
They would generally support the goal of aligning regulatory and payment timing while calling for measurable evaluation and limited, transparent implementation details.
A mainstream conservative would generally favor reducing government-imposed delays that limit patient access to market-approved medical technologies and view the bill as pro-innovation and pro-patient choice.
They would appreciate the budget-neutral requirement, though some may be wary of any expansion of Medicare payment programs or new administrative rules.
They might prefer ensuring the policy does not become a recurring entitlement or create open-ended spending pressures.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise this is a narrow, technical amendment that fits established patterns of incremental Medicare fixes which often succeed, particularly when backed by industry and patient groups. The bill's modest scope and built-in limits raise its prospects. Key barriers are procedural (committee consideration, CBO scoring, Senate floor procedures) and potential pushback if the budget-neutrality claim is found unworkable or if CMS implementation raises cost concerns.
The bill has not accumulated any surfaced votes yet.
Safety and evidence standards: liberals emphasize concerns about devices cleared via 510(k) and want stronger post-market data; conservativ…
Content-wise this is a narrow, technical amendment that fits established patterns of incremental Medicare fixes which often succeed, partic…
Relative to its intended legislative type, this bill is a narrowly focused substantive policy change that amends Medicare payment law to expand NTAP eligibility for FDA-designated breakthrough devices. It provides targe…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.